The assumption that newer means safer is a persistent blind spot in performance enhancement culture. As peptide compounds quietly displace traditional anabolic steroids among recreational lifters and competitive athletes alike, a critical gap has opened between their marketed promise and the actual clinical evidence — a gap with real health consequences for a much larger population than anti-doping agencies typically monitor.
This review, published in the Journal of Sports Medicine and Physical Fitness, systematically examines the pharmacological landscape of peptide and peptide-analog use in sport. The compounds under scrutiny include growth hormone secretagogues such as Ipamorelin, GHRH analogues including CJC-1295 and Sermorelin, and synthetic hormone fragments like Frag 176-191 and the anti-inflammatory peptide KPV. These agents are engineered for enhanced receptor selectivity and metabolic stability compared to conventional peptides, properties that have made them appealing for muscle hypertrophy, fat oxidation, accelerated recovery, and injury mitigation. The review identifies emerging safety signals including cardiovascular strain, insulin resistance, dyslipidemia, and psychiatric disturbance, particularly under the supraphysiological, stacked-dosing protocols prevalent in bodybuilding communities — protocols that bear little resemblance to the controlled therapeutic regimens studied in clinical research.
What makes this review analytically valuable is its dual focus on regulatory and epidemiological failure. WADA has expanded peptide detection methodologies, but the structural similarity of many peptides to endogenous hormones, combined with their short plasma half-lives, continues to frustrate reliable testing. Perhaps more consequentially, the review highlights that peptide misuse is no longer confined to elite sport — recreational users operating through loosely regulated online supply chains face compounding risks from mislabeled or contaminated products. From a public health standpoint, this is arguably more urgent than the doping detection problem. The evidence base remains largely preclinical or derived from therapeutic contexts, meaning population-level safety data are effectively nonexistent. This is an incremental but important synthesis that clarifies risk contours for a rapidly growing exposure.
